Boeing, battery maker at odds over 787 fix - report
SAN FRANCISCO (Reuters) - Boeing Co (BA.N) and the Japanese company that makes lithium-ion batteries for Boeing's 787 Dreamliner disagree about what should be included in a package of measures aimed at getting the airliner back in the air, the Wall Street Journal reported on Wednesday, citing government and industry officials.
Battery maker GS Yuasa Corp (6674.T) believes the fix for the battery should include a voltage regulator that could stop electricity from entering the battery, the Journal said.
Boeing proposed its fix to the FAA on Friday, but on Thursday, Yuasa told the agency that its laboratory tests indicated a power surge outside the battery, or other external problem, started the failures on two batteries, according to the newspaper.
The FAA confirmed the meeting with Yuasa, but did not give any details.
A Yuasa spokesman declined to comment. Boeing spokesman Marc Birtel said that the investigation has not showed that overcharging was a factor and that the 787 had quadruple-redundant protection against overcharging in any case.
"Our proposal includes multiple layers of protection covering the known potential probable causes of the events," Birtel said by email.
He did not respond directly to the comments about Yuasa, although he added that Boeing was coordinating with key suppliers.
No comment was immediately available from Securaplane, the company that makes the charger for the battery.
(Reporting By Jim Wolf, Andrea Shalal-Esa, Mari Saito and Peter Henderson; Editing by M.D. Golan and Andre Grenon)
- Tweet this
- Share this
- Digg this
- Boxer Sarita Devi faces action after refusing medal at Asian Games
- Hong Kong's embattled leader believes protests could last weeks-source
- Ebola outbreaks in Nigeria, Senegal, appear contained: CDC reports
- UPDATE 2-EU-Russia gas duel deepens with Slovakia supply cut
- Obama, Modi work to deepen improving U.S.-India ties
India could run out of a critical medicine in its free HIV/AIDS drugs programme in three weeks due to bureaucratic bungling, a senior government official said, leaving more than 150,000 sufferers without life-saving drugs for about a month. Full Article